Edward Uchio
University of California, Irvine · 207 works · 5,487 citations · h-index 33
Top works
- Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
- Mistaken Identifiers: Gene name errors can be introduced inadvertently when using Excel in bioinformatics
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
- Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
- WATER II (80–150 mL) procedural outcomes
- Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
- Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup
- Laparoscopic Management of Extra-Adrenal Pheochromocytoma
- Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
- Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans
- Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
- Rhodiola rosea L.: an Herb with Anti-Stress, Anti-Aging, and Immunostimulating Properties for Cancer Chemoprevention
- Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results
- ‘Race’ and Prostate Cancer Mortality in Equal-access Healthcare Systems
- Aquablation for benign prostatic hyperplasia in large prostates (80–150 mL): 6‐month results from the WATER II trial
- Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.
- CORTICAL EVOKED POTENTIALS OF THE DORSAL NERVE OF THE CLITORIS AND FEMALE SEXUAL DYSFUNCTION IN MULTIPLE SCLEROSIS